Sign in

John Digman

@jdigman.bsky.social
185 followers 90 following 10 posts

Clinical Pharmacist working in Primary Care, Husband, Father, Disciple of Jesus Christ. Interested in Clinical Pharmacy, General Practice, Politics, Christianity.

PostsRepliesMedia
Reposted by John Digman
Lars Mølgaard Saxhaug @load-dependent.eurosky.social · 09/11/2025
Fascinating paper suggesting the assumption that there is a sigmoid dose response relationship and threshold effect ( "all-or-nothing") for loop diuretics rests on repeated misinterpretation of original studies from the 70s and 80s. #nephsky #cardiosky #emimcc academic.oup.com/ehjcvp/artic...
academic.oup.com
What are the pharmacodynamics of loop diuretics?
A recent editorial was entitled ‘Loop diuretics in heart failure: few facts and lots of prejudice’.1 I would argue that we have forgotten or distorted some
4229
Reposted by John Digman
NEJM.org @nejm.org · 02/11/2025
At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. Full ERSPC study results and Research Summary: nej.md/42YYsg7  #MedSky #Oncology
The New England Journal of Medicine                   
European Study of Prostate Cancer Screening — 23-Year Follow-up 
A Research Summary based on Roobol MJ et al. | 10.1056/NEJMoa2503223 | Published on October 30, 2025 

Visual representations of the patients in the trial and the treatments they were assigned.    

Read the full Research Summary at NEJM.org.
093
Reposted by John Digman
NEJM.org @nejm.org · 08/11/2025
Among patients with atherosclerosis or diabetes but no previous myocardial infarction or stroke, evolocumab led to a lower risk of major adverse cardiovascular events than placebo. Full VESALIUS-CV trial results: nej.md/4oWrIN6 #AHA25
American Heart Association Scientific Sessions 2025   
Original Article | Nov 8, 2025 | NEJM.org   
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke 

Figure 1A. 3-Point MACE.   

The NEJM identity sits at the bottom.
2169
Reposted by John Digman
NEJM.org @nejm.org · 09/11/2025
In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: nej.md/43U5Ppo #AHA25
Kaplan–Meier curves of the cumulative incidence of death from any cause, myocardial infarction, or heart failure (the composite primary end point).
02211
Reposted by John Digman
The BMJ @bmj.com · 26/08/2025
New living clinical practice guideline: Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes See our #BMJInfographic for a visual summary of the recommendations www.bmj.com/content/390/...
Infographic
0810
Reposted by John Digman
Owen Gower @owentg.bsky.social · 17/05/2025
Happy 276th birthday Edward Jenner! What a time for vaccination: 154 million lives saved in the last 50 years, tempered with an increase in vaccine preventable diseases across the world, vaccine sceptics in charge in the US, and cuts to overseas aid threatening global immunisation programmes.
Portrait of Edward Jenner leaning against a tree
210429
John Digman @jdigman.bsky.social · 02/05/2025
Exceptionally clear and informative resource.
030
Reposted by John Digman
JAMA @jama.com · 18/04/2025
The risk of venous thromboembolism (VTE) varies across contemporary hormonal contraceptives, with the highest risk associated with combined pills. #MedSky ja.ma/3Y5WQPf
ja.ma
Contemporary Hormonal Contraception and Risk of Venous Thromboembolism
This study assesses the risk of venous thromboembolism of different forms of hormonal contraception, including pills with estrogen and progestin, vaginal rings, patches, progestin-only pills, intrauterine devices, implants, and injections.
064
Reposted by John Digman
Margaret McCartney @mgtmccartney.bsky.social · 28/01/2025
Terminally Ill Adults (End of Life) Bill: call for evidence here's mine margaretmccartney.substack.com/p/terminally... www.parliament.uk/business/new...
parliament.uk
Terminally Ill Adults (End of Life) Bill: call for evidence
Terminally Ill Adults (End of Life) Bill: call for evidence
21710
Reposted by John Digman
ProfMakris @profmakris.bsky.social · 04/12/2024
Paper in this week's NEJM shows that in patients with atrial fibrillation and stable coronary artery disease, edoxaban monotherapy is superior to the combination of edoxaban plus an antiplatelet drug. Major difference was in bleeding rather than reduction in ischaemic events.
11811
Reposted by John Digman
ProfMakris @profmakris.bsky.social · 08/12/2024
Oral HRT increases venous thrombotic risk (VTE). Tibolone increases arterial but not VTE risk. Topical HRT showed no increase in either. Huge prospective Swedish study: 919,614 women of whom 77,512 started HRT. tinyurl.com/85jxatux #HRT
1158
Reposted by John Digman
Margaret McCartney @mgtmccartney.bsky.social · 28/08/2024
Disagree. It’s not the NICE decision that’s disappointing , it’s the drug www.ft.com/content/7762094c-a86d-43…
ft.com
The disappointing Alzheimer’s decision is part of a bigge...
Nice’s ruling on lecanemab demonstrates the lack of readi...
021
John Digman @jdigman.bsky.social · 22/11/2024
Excellently articulated opinion piece from former PM Gordon Brown.
011
John Digman @jdigman.bsky.social · 19/11/2024
Trending in the wrong direction... #AMR #WAAW24 #PharmSky pharmaceutical-journal.com/article/news...
pharmaceutical-journal.com
Antibiotic-resistant infections at highest level since COVID-19 pandemic, finds report
An estimated 66,730 serious antibiotic-resistant infections were reported in 2023, surpassing pre-pandemic levels of 62,314 infections in 2019, a report published by the UK Health Security Agency (UKH...
051
Reposted by John Digman
Helen Hương Kilminster @hpillminster.pharmsky.app · 19/11/2024
MEGA PDF on Incretin therapies by the one and only @drkevinfernando.bsky.social Very topical at the moment for CRM world #PharmSky #Medsky #GPsky #CRM #CardioSky img.medscapestatic.com/vim/live/pro...
0167
Reposted by John Digman
Andy Webb @ajwpharm.bsky.social · 18/11/2024
Excited to share our recent publication exploring a path forward to retire Cockroft Gault and move towards universal eGFR-based medication dosing decisions, a monumental effort led by Wendy St. Peter and the @nkf-professionals.bsky.social doi.org/10.1093/ajhp...
1246
Reposted by John Digman
Paul Forsyth @pharmacisthf.bsky.social · 17/11/2024
CLEAR trial: Should we routinely use Spironolactone after Acute Myocardial Infarction? No! #AHA2024 www.nejm.org/doi/full/10....
nejm.org
Routine Spironolactone in Acute Myocardial Infarction | NEJM
Mineralocorticoid receptor antagonists have been shown to reduce mortality in patients after myocardial infarction with congestive heart failure. Whether routine use of spironolactone is beneficial...
052
John Digman @jdigman.bsky.social · 16/11/2024
GOLD 2025 guidance now available. No dramatic changes to pharmacological management of COPD from my reading. #PharmSky #COPD goldcopd.org/2025-gold-re...
goldcopd.org
2025 GOLD Report - Global Initiative for Chronic Obstructive Lung Disease - GOLD
GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD: 2025 Report Evidence-based strategy document for COPD diagnosis, management, and prevention, with citations from the scientific litera...
170
John Digman @jdigman.bsky.social · 16/11/2024
Interesting conclusion from Cochrane. Are we currently over treating BP in this cohort? Thoughts? #PharmSky #Pharmacy
010
Reposted by John Digman
Paul Forsyth @pharmacisthf.bsky.social · 16/11/2024
SUMMIT trial: “Treatment with tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure than placebo and improved health status in patients with heart failure with preserved ejection fraction and obesity” www.nejm.org/doi/full/10....
nejm.org
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | NEJM
Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor...
153
Reposted by John Digman
Paul Forsyth @pharmacisthf.bsky.social · 16/11/2024
BPROAD trial: “Among patients with T2 diabetes, the incidence of major CVD events was significantly lower with intensive treatment targeting a systolic blood pressure of <120 mm Hg than with standard treatment targeting a systolic blood pressure of <140 mm Hg” www.nejm.org/doi/full/10....
nejm.org
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | NEJM
Effective targets for systolic blood-pressure control in patients with type 2 diabetes are unclear. We enrolled patients 50 years of age or older with type 2 diabetes, elevated systolic blood press...
063
Reposted by John Digman
Anthony Cox @anthonycox.info · 13/11/2024
Good piece on the problems around drug choice in assisted suicide unherd.com/2024/11/the-...
unherd.com
The painful truth about assisted suicide
012
Reposted by John Digman
Rev. Benjamin Cremer @brcremer.bsky.social · 12/11/2024
Partisan prophecy: God warning powerless people of their fate if they do not support and defend the cause of the right people in power. Biblical prophecy: God warning those in power of their fate if they do not support and defend the cause of powerless people.
1844491
John Digman @jdigman.bsky.social · 14/11/2024
I understood that BlueSky was supposed to be a 'safer' space than X... On browsing feeds on Christianity/religion, perhaps this is not a safe space after all! Is there space for people of faith to encourage each other here, or should we move elsewhere?! #christianity #religion #christian
000